StreetInsider.com News Articles

Actinium Pharmaceuticals, Inc. to Present Two Abstracts at the 2026 AACR Annual Meeting

Tue, 17 Feb 2026 07:42:00 -0500

AACR Presentations to Feature ATNM-400 and Actimab-A Programs Across Solid Tumors and Hematologic Oncology Applications

NEW YORK, Feb. 17, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or the "Company"), a pioneer in the development of differentiated targeted radiotherapies, today announced that it will present two abstracts at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place April 17–22, 2026 in San Diego, California.

Actinium Pharmaceuticals, Inc. to Present Two Abstracts at the 2026 AACR Annual Meeting

Tue, 17 Feb 2026 07:42:00 -0500

AACR Presentations to Feature ATNM-400 and Actimab-A Programs Across Solid Tumors and Hematologic Oncology Applications

Actinium Pharmaceuticals, Inc. to Present Two Abstracts at the 2026 AACR Annual Meeting

Tue, 17 Feb 2026 07:42:00 -0500

AACR Presentations to Feature ATNM-400 and Actimab-A Programs Across Solid Tumors and Hematologic Oncology Applications

Actinium Pharmaceuticals, Inc. to Present Two Abstracts at the 2026 AACR Annual Meeting

Tue, 17 Feb 2026 07:42:00 -0500

AACR Presentations to Feature ATNM-400 and Actimab-A Programs Across Solid Tumors and Hematologic Oncology Applications

Actinium Pharmaceuticals, Inc. to Present Two Abstracts at the 2026 AACR Annual Meeting

Tue, 17 Feb 2026 07:42:00 -0500

AACR Presentations to Feature ATNM-400 and Actimab-A Programs Across Solid Tumors and Hematologic Oncology Applications

Actinium Pharmaceuticals, Inc. to Present Two Abstracts at the 2026 AACR Annual Meeting

Tue, 17 Feb 2026 07:42:00 -0500

AACR Presentations to Feature ATNM-400 and Actimab-A Programs Across Solid Tumors and Hematologic Oncology Applications

Actinium Pharmaceuticals, Inc. to Present Two Abstracts at the 2026 AACR Annual Meeting

Tue, 17 Feb 2026 07:42:00 -0500

AACR Presentations to Feature ATNM-400 and Actimab-A Programs Across Solid Tumors and Hematologic Oncology Applications

Actinium Pharmaceuticals, Inc. to Present Two Abstracts at the 2026 AACR Annual Meeting

Tue, 17 Feb 2026 07:42:00 -0500

AACR Presentations to Feature ATNM-400 and Actimab-A Programs Across Solid Tumors and Hematologic Oncology Applications

Actinium Pharmaceuticals, Inc. to Present Two Abstracts at the 2026 AACR Annual Meeting

Tue, 17 Feb 2026 07:42:00 -0500

AACR Presentations to Feature ATNM-400 and Actimab-A Programs Across Solid Tumors and Hematologic Oncology Applications

Actinium Pharmaceuticals, Inc. to Present Two Abstracts at the 2026 AACR Annual Meeting

Tue, 17 Feb 2026 07:42:00 -0500

AACR Presentations to Feature ATNM-400 and Actimab-A Programs Across Solid Tumors and Hematologic Oncology Applications

Actinium Pharmaceuticals, Inc. to Present Two Abstracts at the 2026 AACR Annual Meeting

Tue, 17 Feb 2026 07:42:00 -0500

AACR Presentations to Feature ATNM-400 and Actimab-A Programs Across Solid Tumors and Hematologic Oncology Applications

Actinium Pharmaceuticals, Inc. to Present Two Abstracts at the 2026 AACR Annual Meeting

Tue, 17 Feb 2026 07:42:00 -0500

AACR Presentations to Feature ATNM-400 and Actimab-A Programs Across Solid Tumors and Hematologic Oncology Applications

Form 8-K Actinium Pharmaceuticals For: Feb 11

Fri, 13 Feb 2026 17:01:00 -0500

si-local-file:///var/storage/secattach/20260213/26001718.html

Form 8-K Actinium Pharmaceuticals For: Feb 11

Fri, 13 Feb 2026 17:01:00 -0500

si-local-file:///var/storage/secattach/20260213/26001718.html

Actinium presents breast cancer data for ATNM-400 at medical conference

Fri, 12 Dec 2025 08:45:43 -0500

Actinium Pharmaceuticals Inc. (NYSE American: ATNM) presented preclinical data for its experimental cancer treatment ATNM-400 at the 2025 San Antonio Breast Cancer Symposium. The data showed activity against multiple breast cancer types, including hormone receptor-positive, triple-negative, and treatment-resistant forms.

The company reported that ATNM-400 demonstrated tumor growth inhibition in laboratory models of hormone receptor-positive and triple-negative breast cancer. The treatment also showed activity in models resistant to standard therapies tamoxifen and trastuzumab, according to the press release.

ATNM-400 is designed to deliver Actinium-225 alpha-particle radiation to cancer cells. The treatment targets an antigen that the company states is overexpressed in breast cancer

Actinium presents breast cancer data for ATNM-400 at medical conference

Fri, 12 Dec 2025 08:45:43 -0500

ATNM-400 is designed to deliver Actinium-225 alpha-particle radiation to cancer cells. The treatment targets an antigen that the company states is overexpressed in breast cancer

Actinium presents breast cancer data for ATNM-400 at medical conference

Fri, 12 Dec 2025 08:45:43 -0500

ATNM-400 is designed to deliver Actinium-225 alpha-particle radiation to cancer cells. The treatment targets an antigen that the company states is overexpressed in breast cancer

Actinium presents breast cancer data for ATNM-400 at medical conference

Fri, 12 Dec 2025 08:45:43 -0500

ATNM-400 is designed to deliver Actinium-225 alpha-particle radiation to cancer cells. The treatment targets an antigen that the company states is overexpressed in breast cancer

Actinium Pharmaceuticals Presents New Preclinical Data Demonstrating Potent Anti-Tumor Activity of ATNM-400 Across Multiple Breast Cancer Subtypes Including Hormone Receptor-Positive, Triple-Negative,

Fri, 12 Dec 2025 08:45:00 -0500

- ATNM-400's target antigen is overexpressed in breast cancer and its expression is further increased in breast cancer cells resistant to standard of care endocrine therapy, tamoxifen and the HER2 therapy trastuzumab

- The Actinium-225 alpha-emitter payload of ATNM-400 induced irreversible double-strand DNA breaks and has the potential to produce potent localized tumor killing with reduced off-target lung toxicity that limits the use of antibody drug conjugates

- Data supports the continued development of ATNM-400 as a monotherapy or combination therapy to address multiple breast cancer subtypes with limited treatment options

NEW YORK, Dec.

Actinium Pharmaceuticals Presents New Preclinical Data Demonstrating Potent Anti-Tumor Activity of ATNM-400 Across Multiple Breast Cancer Subtypes Including Hormone Receptor-Positive, Triple-Negative,

Fri, 12 Dec 2025 08:45:00 -0500

- Data supports the continued development of ATNM-400 as a monotherapy or combination therapy to address multiple breast cancer subtypes with limited treatment options

NEW YORK, Dec.

Actinium Pharmaceuticals Presents New Preclinical Data Demonstrating Potent Anti-Tumor Activity of ATNM-400 Across Multiple Breast Cancer Subtypes Including Hormone Receptor-Positive, Triple-Negative,

Fri, 12 Dec 2025 08:45:00 -0500

- Data supports the continued development of ATNM-400 as a monotherapy or combination therapy to address multiple breast cancer subtypes with limited treatment options

NEW YORK, Dec.

Actinium Pharmaceuticals Presents New Preclinical Data Demonstrating Potent Anti-Tumor Activity of ATNM-400 Across Multiple Breast Cancer Subtypes Including Hormone Receptor-Positive, Triple-Negative,

Fri, 12 Dec 2025 08:45:00 -0500

- Data supports the continued development of ATNM-400 as a monotherapy or combination therapy to address multiple breast cancer subtypes with limited treatment options

NEW YORK, Dec.

Actinium Pharmaceuticals Presents New Preclinical Data Demonstrating Potent Anti-Tumor Activity of ATNM-400 Across Multiple Breast Cancer Subtypes Including Hormone Receptor-Positive, Triple-Negative,

Fri, 12 Dec 2025 08:45:00 -0500

- Data supports the continued development of ATNM-400 as a monotherapy or combination therapy to address multiple breast cancer subtypes with limited treatment options

NEW YORK, Dec.

Actinium Pharmaceuticals Presents New Preclinical Data Demonstrating Potent Anti-Tumor Activity of ATNM-400 Across Multiple Breast Cancer Subtypes Including Hormone Receptor-Positive, Triple-Negative,

Fri, 12 Dec 2025 08:45:00 -0500

- Data supports the continued development of ATNM-400 as a monotherapy or combination therapy to address multiple breast cancer subtypes with limited treatment options

NEW YORK, Dec.

Actinium Pharmaceuticals Presents New Preclinical Data Demonstrating Potent Anti-Tumor Activity of ATNM-400 Across Multiple Breast Cancer Subtypes Including Hormone Receptor-Positive, Triple-Negative,

Fri, 12 Dec 2025 08:45:00 -0500

- Data supports the continued development of ATNM-400 as a monotherapy or combination therapy to address multiple breast cancer subtypes with limited treatment options

NEW YORK, Dec.